High-Load Core@Shell Nanocarriers with Irinotecan and 5-Fluorouracil for Combination Chemotherapy in Colorectal Cancer

被引:0
作者
Notter, Silke [1 ]
Choezom, Dolma [2 ,3 ,4 ]
Griebel, Titus [2 ,3 ]
Ramos-Gomes, Fernanda [3 ]
Moebius, Wiebke [3 ]
De Oliveira, Tiago [4 ]
Conradi, Lena-Christin [4 ]
Alves, Frauke [2 ,3 ,5 ]
Feldmann, Claus [1 ]
机构
[1] Karlsruhe Inst Technol KIT, Inst Inorgan Chem, Engesserstr 15, D-76131 Karlsruhe, Germany
[2] Univ Med Ctr Goettingen UMG, Clin Haematol & Med Oncol, Robert Koch Str 40, D-37075 Gottingen, Germany
[3] Max Planck Inst Multidisciplinary Sci MPI NAT, Dept Neurogenet, City Campus,Hermann Rein Str 3, D-37075 Gottingen, Germany
[4] Univ Med Ctr Goettingen UMG, Dept Gen Visceral & Pediat Surg, Robert Koch Str 40, D-37075 Gottingen, Germany
[5] Univ Med Ctr Goettingen UMG, Inst Diagnost & Intervent Radiol, Robert Koch Str 40, D-37075 Gottingen, Germany
来源
SMALL SCIENCE | 2024年 / 4卷 / 11期
关键词
5-fluorouracil; colorectal cancer; drug delivery; irinotecan; tumor combination therapy; DRUG-DELIVERY; NANOPARTICLES; PACLITAXEL; PROGRESS; TRIAL;
D O I
10.1002/smsc.202400196
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Colorectal cancer (CRC) is the third most common cancer type and second leading cause of cancer-related deaths worldwide, requiring novel drug-delivery concepts. ITC@ZrO(TocP)/ZrO(FdUMP) core@shell nanocarriers (designated ITC-FdUMP-NC) with the clinically relevant chemotherapeutics irinotecan (ITC) and fluoro-2 '-deoxyuridine-5 '-phosphate (FdUMP) (active derivative of 5 '-fluorouracil/5-FU) are a new type of nanocarrier with high drug payload (22 wt% of lipophilic ITC: particle core; 10 wt% of hydrophilic FdUMP: particle shell). The nanocarriers are tested in different CRC cell lines, a normal cell line, and rectal cancer patient-derived organoids (PDOs). Fluorescence-labeled nanocarriers show efficient uptake by all CRC cells and allow to distinctly track the intracellular trafficking toward endolysosomal compartments. Although free chemotherapeutic drugs exhibit a greater potency in 2D cell cultures, ITC-FdUMP-NC demonstrate equivalent cytotoxic efficacies as the freely dissolved drugs in the more complex 3D rectal cancer PDOs. The sustained drug-release profile of the nanocarriers contrasts favorably with conventional free drugs, potentially enhancing the therapeutic outcome in vivo. With a chemotherapeutic cocktail comparable to the clinically applied FOLFIRI (ITC + 5-FU), the ITC-FdUMP-NC represent a novel type of nanocarrier with high anti-tumor effect and high drug payload, offering a promising strategy to circumvent chemoresistance and to improve therapy efficacy in vivo with less side effects. A clinically relevant drug cocktail of irinotecan (ITC) and 5-fluorouridine (5-FU) is combined in a single nanocarrier with high drug payload (32%). The nanocarriers show efficient uptake and high efficacy in different human colon cancer and human rectal cancer cell lines as well as rectal cancer patient-derived organoids, also allowing to elucidate the membrane-trafficking pathway.image (c) 2024 WILEY-VCH GmbH
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer
    D Cunningham
    S Falk
    D Jackson
    British Journal of Cancer, 2002, 86 : 1677 - 1683
  • [22] Outpatient therapy with irinotecan and low-dose cisplatin for metastatic colorectal cancer resistant to 5-fluorouracil
    Shimada, S
    Yagi, Y
    Shiomori, K
    Kuramoto, M
    Aoki, N
    Ogawa, M
    ONCOLOGY REPORTS, 2002, 9 (04) : 783 - 787
  • [23] Combination of irinotecan, oxaliplatin and 5-fluorouracil as a rechallenge regimen for heavily pretreated metastatic colorectal cancer patients
    Fernandes G.D.S.
    Braghiroli M.I.
    Artioli M.
    Paterlini A.C.C.R.
    Teixeira M.C.
    Gumz B.P.
    Girardi D.M.
    Braghiroli O.F.M.
    Costa F.P.
    Hoff P.M.
    Journal of Gastrointestinal Cancer, 2018, 49 (4) : 470 - 475
  • [24] Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC)
    Kouroussis, C
    Souglakos, J
    Mavroudis, D
    Papadouris, S
    Kakolyris, S
    Agelaki, S
    Kalbakis, K
    Panopoulos, C
    Vardakis, N
    Sarra, E
    Georgoulias, V
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (06): : 627 - 631
  • [25] Delivery of Rapamycin by Liposomes Synergistically Enhances the Chemotherapy Effect of 5-Fluorouracil on Colorectal Cancer
    Chen, Yi-Qing
    Zhu, Wen-Ting
    Lin, Cai-Yan
    Yuan, Zhong-Wen
    Li, Zhen-Hua
    Yan, Peng-Ke
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2021, 16 : 269 - 281
  • [26] Melatonin and 5-fluorouracil combination chemotherapy: opportunities and efficacy in cancer therapy
    Mafi, Alireza
    Rezaee, Malihe
    Hedayati, Neda
    Hogan, Sara Diana
    Reiter, Russel J.
    Aarabi, Mohammad-Hossein
    Asemi, Zatollah
    CELL COMMUNICATION AND SIGNALING, 2023, 21 (01)
  • [27] Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer
    Huang, Xingxing
    Ke, Kun
    Jin, Weiwei
    Zhu, Qianru
    Zhu, Qicong
    Mei, Ruyi
    Zhang, Ruonan
    Yu, Shuxian
    Shou, Lan
    Sun, Xueni
    Feng, Jiao
    Duan, Ting
    Mou, Yiping
    Xie, Tian
    Wu, Qibiao
    Sui, Xinbing
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [28] In vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer
    Inoue, Y
    Tanaka, K
    Hiro, J
    Yoshiyama, S
    Toiyama, Y
    Eguchi, T
    Miki, C
    Kusunoki, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2006, 28 (02) : 479 - 486
  • [29] Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model
    Zhu, Guangwei
    Zhao, Ming
    Han, Qinghong
    Tan, Yuying
    Sun, Yu
    Bouvet, Michael
    Clary, Bryan
    Singh, Shree Ram
    Ye, Jianxin
    Hoffman, Robert M.
    ANTICANCER RESEARCH, 2019, 39 (12) : 6463 - 6470
  • [30] Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study
    Aranda, E.
    Valladares, M.
    Martinez-Villacampa, M.
    Benavides, M.
    Gomez, A.
    Massutti, B.
    Marcuello, E.
    Constenla, M.
    Camara, J. C.
    Carrato, A.
    Duenas, R.
    Reboredo, M.
    Navarro, M.
    Diaz-Rubio, E.
    ANNALS OF ONCOLOGY, 2009, 20 (02) : 251 - 257